KMT2A and leukemia: NK cell transfer to NSG mice increased, whereas depletion of NK cells with anti-NK1.1 antibody from C57BL/6 mice reduced the therapeutic effect of DS-5272 against MLL-AF9 leukemia (Fig. 7d, e).